Vitiligo-like lesions in an adult patient treated with Imatinib mesylate

Leukemia Research

Volumn 33, Issue 8, 2009, Pages

  Cerchione, C ^a   Fabbricini, R ^a   Pane, F ^a   Luciano, L ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTHRALGIA; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FLUID RETENTION; HEMODYNAMIC PARAMETERS; HEPATOMEGALY; HUMAN; HUMAN TISSUE; HYBRID GENE; HYPOPIGMENTATION; LETTER; MALE; MYALGIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; SPLENOMEGALY; TREATMENT OUTCOME; VITILIGO; XEROSTOMIA;

ADULT; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; VITILIGO;

EID: 67349257169     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.023     Document Type: Letter

References (13)

1. Tsao A.S., Kantarjian H., Cortes J., et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 98 (2003) 2483-2487
2. Alexandrescu D.T., Dasanu C.A., Farzanmehr H., and Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 14 (2008) 7
3. Ayirookuzhi S.J., Ma L., Ramshesh P., and Mills G. Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol 141 (2005) 368-370
4. Pascual J.C., Matarredona J., Miralles J., Conesa V., and Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 45 (2006) 1471-1473
5. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
6. Dippel E., Haas N., Grabbe J., Schadendorf D., Hamann K., and Czarnetzki B.M. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol 132 (1995) 182-189
7. Grichnik J.M., Burch J.A., Burchette J., et al. The SCF-KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 111 (1998) 233-238
8. Nomura K., Hatayama I., Narita T., Kaneko T., and Shiraishi M. A novel KIT gene missense mutation in a Japanese family with piebaldism. J Invest Dermatol 111 (1998) 337-338
9. Richards K.A., Fukai K., Oiso N., and Paller A.S. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol 44 (2001) 288-292
10. Sharma A., Vora A., and Bhutani M. Generalized hypopigmentation due to imatinib: a fairness boon?. Indian J Dermatol Venereol Leprol 71 (2005) 45-46
11. McPartlin S., and Leach M. Loss of skin pigment caused by imatinib therapy. Br J Haematol 129 (2005) 448
12. Longley B.J., and Carter El. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol 113 (1999) 139-140
13. Cario-André M., Ardilouze L., Pain C., Gauthier Y., Mahon F.X., and Taieb A. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol 155 (2006) 493-494